In this video, Xiuning Le, MD, PhD, discusses how the definition of EGFR-mutated lung cancer has expanded in recent years.

Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).

Like Tagrisso, J&J's regimen blocks the EGFR protein to prevent cancer cells from growing. It also targets MET, a common pathway cancer uses to develop resistance to drugs. J&J forecasts Rybrevant ...

Image: Adobe Stock. As part of a dedicated Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions, the NKF recommends researchers and providers switch from the Cockcroft ...

we are far from a consensus regarding the criteria for the use of anti-EGFR drugs. Unsatisfactory results in clinical trials invariably bring forth issues regarding lack of proper patient ...

Tagrisso has been recommended as an adjuvant therapy following complete surgical resection in adults with stage 1B to 3A ...

That's important for AZ, as Tagrisso is starting to face the threat of competition from other EGFR drugs, including Johnson & Johnson's fast-growing EGFRxMET bispecific antibody Rybrevant ...

The molecular basis and mechanisms of action of combining classic cytotoxic agents (e.g. platinum-containing drugs, taxanes, etc.) and novel agents (e.g. tirapazamine, EGFR inhibitors and other ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...